Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia - report from ASH 2025

Hanny Al-Samkari discusses the results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia who failed first-line corticosteroid treatment at the American Society of Hematology's 67th Annual Meeting.Video: https://medicaldigest.org/scientific-contents/interview:novel-agent-ianalumab-added-standard-therapy-extends-time-treatment-failure-patients-previously-treated-immune-thrombocytopenia